![Elisabeth Oelmann](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Elisabeth Oelmann formerly worked at Kymab Ltd., as Senior Medical Director, PRA International LLC, as Medical Director-Oncology Europe Region, and NuCana Plc, as Senior VP-Medical & Clinical Development from 2020 to 2025.
Dr. Oelmann received her doctorate degree from the University of Münster.
Anciens postes connus de Elisabeth Oelmann
| Sociétés | Poste | Fin |
|---|---|---|
| NUCANA PLC | Directeur Technique/Scientifique/R&D | 01/09/2025 |
PRA International LLC
 PRA International LLC Pharmaceuticals: OtherHealth Technology Operates as a clinical research organization | Corporate Officer/Principal | - |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Discovers and develops human monoclonal antibody drugs | Directeur Technique/Scientifique/R&D | - |
Formation de Elisabeth Oelmann
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
1
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
University of Münster
 University of Münster Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Discovers and develops human monoclonal antibody drugs | Health Technology |
NuCana Plc
 NuCana Plc BiotechnologyHealth Technology Develops and commercializes novel anti-cancer medicines | Health Technology |
PRA International LLC
PRA International LLC Pharmaceuticals: OtherHealth Technology Operates as a clinical research organization | Health Technology |
Choisissez Zonebourse 
